Pain reliever lowers blood sugar in type 2 diabetics, study says

July 1, 2013 by Serena Gordon, Healthday Reporter
Pain reliever lowers blood sugar in type 2 diabetics, study says
But side effects of aspirin-like drug warrant further study.

(HealthDay)— An aspirin-like drug appears to lower blood sugar in people with type 2 diabetes, according to new research.

A study of the drug—the prescription salsalate—also found it reduced inflammation associated with type 2 diabetes. But it produced unwelcome side effects that could limit its potential as a diabetes treatment.

"This trial is a test of possibly the oldest drug in Western use, and, because it's so old, there are no clinical trials on it," said study senior author Dr. Steven Shoelson, a professor of medicine at Harvard Medical School in Boston.

"This trial was for a full year and showed that salsalate does lower ," said Shoelson, who is also the associate research director at the Joslin Diabetes Center in Boston.

The study, published in the July 2 issue of the Annals of Internal Medicine, included 286 people between 18 and 75 years old with type 2 diabetes. Type 2 diabetes occurs when the body no longer produces enough of the to convert carbohydrates from food into fuel for the body.

At the start of the study, the participants' average A1C levels—a measure of over several months—were between 7 and 9.5 percent. The American Diabetes Association generally recommends a level of below 7 percent for adults.

The study volunteers were randomly assigned to 48 weeks of salsalate at a dose of 3.5 grams per day, or to an inactive . No other changes were made to current diabetes, blood pressure or cholesterol medications during the first six months of the trial, the researchers noted.

Over 48 weeks, people taking the medication saw their A1C levels drop by 0.37 percent compared to placebo.

Shoelson said that people who have —a group of (including type 2 diabetes) for cardiovascular disease—often have higher than normal white blood cell counts, suggesting inflammation. In this study, people on salsalate saw a drop in their white blood cell counts, but Shoelson noted that they were "always well within the normal range."

Improvements were seen in several areas among those taking the drug, including: fasting ; uric acid, which is a chemical associated with gout; and levels of triglyceride, a type of blood fat. Levels of adiponectin—a substance related to decreased insulin resistance—and hematocrit, a measure of red blood cells, also improved for people taking salsalate.

Not all of the changes linked to the drug were beneficial, however. The medication appeared to cause a slight weight gain—less than 3 pounds compared to those taking the placebo. Many type 2 diabetes medications have weight gain as a side effect, Shoelson said.

Salsalate was also linked to an increase in LDL cholesterol, which is associated with heart disease. "There was a small elevation in LDL cholesterol, and we prefer not to see that, although we can bring it down with [cholesterol-lowering drugs]," he said.

Elevated urinary albumin levels, which can indicate reduced kidney function, were also seen among those taking the drug but albumin levels returned to normal when the drug was stopped, Shoelson said.

No increase in gastrointestinal bleeding was reported in those on salsalate, which had been a concern because the drug is a chemical cousin of aspirin, he added.

At this point, it's premature to recommend the use of salsalate for people with , Shoelson said. "I would like to see further clinical trials and studies, and the [U.S. Food and Drug Administration] likes to see information on cardiovascular and long-term risks," he noted.

Dr. Joel Zonszein, director of the clinical diabetes center at Montefiore Medical Center in New York City, said he doubts the FDA will approve salsalate for treatment. "This medication has a lot of limitations and side effects, and it doesn't cause a significant drop in the A1C," said Zonszein.

Diet and exercise could cause many of the reported changes, such as the increase in adiponectin, he said. If this medication were reducing inflammation, significant changes would be seen in highly sensitive C-reactive protein (CRP), and none were noted here, he added.

"Drugs like Actos or Avandia drop CRP by 20, 30, even 50 percent, and here there wasn't a significant drop," said Zonszein.

Salsalate is marketed under the brand names Salsitab, Mono-Gesic, Salflex and Disalcid.

Explore further: ADA: Salsalate doesn't up endothelial function in T2DM

More information: Learn more about type 2 diabetes medications from the American Diabetes Association.

Related Stories

ADA: Salsalate doesn't up endothelial function in T2DM

June 12, 2012
(HealthDay) -- For patients with type 2 diabetes (T2D), treatment with salsalate does not improve endothelial function as measured by flow-mediated, endothelium-dependent dilation (FMD), although it is associated with lower ...

New type 2 diabetes drug helps lower blood sugar: study

March 20, 2012
(HealthDay) -- A new type of medication for type 2 diabetes helps to lower blood sugar levels when used in concert with insulin and other diabetes drugs, new research suggests.

Diabetes groups issue new guidelines on blood sugar

April 19, 2012
(HealthDay) -- Type 2 diabetes is a complex metabolic disorder, and treating the disease often requires a personalized, multi-pronged approach, say new expert guidelines on treating high blood sugar levels, issued Thursday.

Starting on three drugs at time of diagnosis benefits Type 2 diabetics

June 24, 2013
Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher ...

Recommended for you

People who drink 3 to 4 times per week less likely to develop diabetes than those who never drink: study

July 27, 2017
Frequent alcohol consumption is associated with a reduced risk of diabetes in both men and women, according to a new study published in Diabetologia (the journal of the European Association for the Study of Diabetes), with ...

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.